SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2020 / Cilt: 4 - Sayı: 3

How do Functional Tear Tests and Corneal and Anterior Chamber Parameters Change After Topical Cyclosporine -A 0.05% Treatment in Dry Eye Diagnosed Women?

Esra ŞAHLI
Cemal ÇAVDARLI
Pages
384–389
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objectives: To report the effects of cyclosporine-A 0.05% on functional tear tests, corneal thickness and anterior chamber parameters in dry eye (DED) diagnosed women.Methods: Thirty-eyes of 30 women with DED symptoms and Schirmer test scores of ≤5 mm/ 5 min with tear break-uptime (BUT)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To report the effects of cyclosporine-A 0.05% on functional tear tests, corneal thickness and anterior chamber parameters in dry eye (DED) diagnosed women.Methods: Thirty-eyes of 30 women with DED symptoms and Schirmer test scores of ≤5 mm/ 5 min with tear break-uptime (BUT)
📊
Key Findings & Data:Objectives: To report the effects of cyclosporine-A 0.05% on functional tear tests, corneal thickness and anterior chamber parameters in dry eye (DED) diagnosed women.Methods: Thirty-eyes of 30 women with DED symptoms and Schirmer test scores of ≤5 mm/ 5 min with tear break-uptime (BUT)
💡
Conclusion & Impact:Objectives: To report the effects of cyclosporine-A 0.05% on functional tear tests, corneal thickness and anterior chamber parameters in dry eye (DED) diagnosed women.Methods: Thirty-eyes of 30 women with DED symptoms and Schirmer test scores of ≤5 mm/ 5 min with tear break-uptime (BUT)
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To report the effects of cyclosporine-A 0.05% on functional tear tests, corneal thickness and anterior chamber parameters in dry eye (DED) diagnosed women.Methods: Thirty-eyes of 30 women with DED symptoms and Schirmer test scores of ≤5 mm/ 5 min with tear break-uptime (BUT)

🔖

Cite This Article

ŞAHLI, E., ÇAVDARLI, C. (2022). How do Functional Tear Tests and Corneal and Anterior Chamber Parameters Change After Topical Cyclosporine -A 0.05% Treatment in Dry Eye Diagnosed Women?. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 3, 384–389. https://ajindex.com/articles/508667

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:93–107
  2. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II Report Executive Summary. Ocul Surf 2017;15:802–12
  3. Pflugfelder SC, Farley W, Luo L, Chen LZ, de Paiva CS, Olmos LC, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol 2005;166:61–71
  4. Yoon KC, De Paiva CS, Qi H, Chen Z, Farley WJ, Li DQ, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 Mice: effects of desiccating stres. Invest Ophthalmol Vis Sci 2007;48:2561–69
  5. Tatlipinar S, Akpek EK. Topical cyclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005;89:1363–67
  6. Cordero-Coma M, Anzaar F, Sobrin L, Foster CS. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Ocul Immunol Inflamm 2007;15:99–104
  7. Sahli E, Hoşal BM, Zilelioğlu G, Gülbahçe R, Ustün H. The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye. Cornea 2010;29:1412–6
  8. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002;120:330–37
  9. Kim EC, Choi JS, Joo CK. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 2009;147:206–213
  10. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007;114:76–79
  11. Pflugfelder SC, Corrales RM, de Paiva CS. T-helper cytokines in dry eye disease. Exp Eye Res 2013;117:118–25
  12. Lackner B, Schmidinger G, Pieh S, Funovics MA, Skorpik C. Repeatability and reproducibility of central corneal thickness measurement with pentacam, orbscan, and ultrasound. Optom Vis Sci 2005;82:892–8
  13. Anayol MA, Bostancı B, Şekeroğlu MA, Şimşek M, Günaydın S, Yılmazbaş P. Assessment of Corneal Densitometry in Rheumatoid Arthritis Patients. Turk J Ophthalmol 2017;47:125–9
  14. Cingü AK, Cınar Y, Türkcü FM, Sahin M, Kaya S, Bozkurt M,etal. Evaluation of corneal parameters with scheimpflug imaging in patients with rheumatoid arthritis. Ocul Immunol Inflamm 2013;21:360–365
  15. Prata TS, Sousa AK, Garcia Filho CA, Doi LM, Paranh